(Q35219226)

7 August 2017

0 references

Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis (English)

1 reference

7 August 2017

1 reference

hepatocellular carcinoma

1 reference

1 reference

Man Yang

1

1 reference

7 August 2017

Jin-Qiu Yuan

series ordinal

2

1 reference

7 August 2017

Ming Bai

series ordinal

3

1 reference

7 August 2017

Guo-Hong Han

series ordinal

4

1 reference

7 August 2017

publication date

5 August 2014

1 reference

Molecular Biology Reports

7 August 2017

published in

1 reference

7 August 2017

volume

41

1 reference

7 August 2017

issue

10

1 reference

7 August 2017

page(s)

6575-6582

1 reference

https://scigraph.springernature.com/pub.10.1007/s11033-014-3541-7

7 August 2017

exact match

0 references

cites work

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3541-7

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3541-7

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3541-7

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3541-7

Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3541-7

Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3541-7

Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3541-7

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3541-7

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3541-7

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3541-7

Practical methods for incorporating summary time-to-event data into meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3541-7

Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3541-7

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3541-7

Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3541-7

Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3541-7

The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3541-7

Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3541-7

A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3541-7

Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomised and observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3541-7

Meta-analysis of three randomized trials and nine observational studies comparing drug-eluting stents versus coronary artery bypass grafting for unprotected left main coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3541-7

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-014-3541-7

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25091939

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11033-014-3541-7

1 reference

7 August 2017

1 reference